Treatment of Febrile illness with artemisinin combination therapy: Prevalence and predictors in five African household surveys

Journal of Pharmaceutical Policy and Practice

Volumn 8, Issue 1, 2015, Pages 1-9

  Vialle Valentin, Catherine E ^a   LeCates, Robert F ^a   Zhang, Fang ^a   Ross Degnan, Dennis ^a  

^a HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

Author keywords

Africa; Appropriate use of medicines; Artemisinin combination therapy; Household surveys

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTEMETHER; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; HALOFANTRINE; MEFLOQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; UNCLASSIFIED DRUG;

ADULT; AFRICAN; ARTICLE; DRUG COST; DRUG UTILIZATION; FEMALE; FEVER; GAMBIA; GHANA; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH SURVEY; HELP SEEKING BEHAVIOR; HOUSEHOLD; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALARIA; MALE; MEDICAL DECISION MAKING; NIGERIA; PREVALENCE; PUBLIC HEALTH SERVICE; SOCIAL STATUS; UGANDA; WORLD HEALTH ORGANIZATION;

EID: 84983161246     PISSN: None     EISSN: 20523211     Source Type: Journal    
DOI: 10.1186/s40545-014-0024-0     Document Type: Article

References (30)

1. Report of a WHO Technical Consultation. Antimalarial Drug Combination Therapy. Geneva: World Health Organization; 2001. [http: //www. who. int/ malaria/publications/atoz/who_cds_rbm_2001_35/en/]. Accessed October 20, 2014.
2. Nyarango PM, Gebremeskel T, Mebrahtu G, Mufunda J, Abdulmumini U, Ogbamariam A, et al. A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. Malar J. 2006; 5: 33.
3. Bhattarai A, Ali AS, Kachur SP, Martensson A, Abbas AK, Khatib R, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 2007; 4(11): e309.
4. Roll Back Malaria. Global strategic plan 2005-2015. [http: //www. rbm. who. int/forumV/docs/gsp_en. pdf. 2008] Accessed October 20, 2014.
5. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009; 3: CD007483.
6. Rational Pharmaceutical Management Plus Center for Pharmaceutical Management. Changing malaria treatment policy to artemisinin-based combinations; an implementation guide. Management Sciences for Health. 2005. [http: //www. msh. org/sites/msh. org/files/malaria_treatment_ policy_en_0. pdf] Accessed October 20, 2014.
7. AMFm task force of the Roll Back Malaria Partnership. Affordable medicines facility - malaria (AMFm). Roll Back Malaria. 2007. [http: //www. rbm. who. int/ multimedia/partnershippublications. html#2007] Accessed October 20, 2014.
8. Abdalla SI, Malik EM, Ali KM. The burden of malaria in Sudan: incidence, mortality and disability-adjusted life-years. Malar J. 2007; 6: 97.
9. Marsh VM, Mutemi WM, Willetts A, Bayah K, Were S, Ross A, et al. Improving malaria home treatment by training drug retailers in rural Kenya. Trop Med Int Health. 2004; 9(4): 451-60.
10. Roll Back Malaria: Monitoring and Evaluation Reference Group. Malaria Indicator Survey: basic documentation for survey design and implementation. [http: //whqlibdoc. who. int/publications/2005/ 9241593571_eng. pdf] Accessed October 20, 2014.
11. MEASURE DHS. Demographic and Health Surveys. [http: //www. dhsprogram. com/] Accessed October 20, 2014.
12. WHO. World malaria report 2011. World Health Organization. 2011. [http: //www. who. int/malaria/world_malaria_report_2011/en/] Accessed October 20, 2014.
13. Littrell M, Gatakaa H, Evance I, Poyer S, Njogu J, Solomon T, et al. Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries. Malar J. 2011; 10: 327.
14. WHO. Guidelines for the treatment of malaria, second edition. 2010. [http: //www. who. int/malaria/publications/atoz/9789241547925/en/] Accessed October 20, 2014.
15. Vialle-Valentin CE, Lecates RF, Zhang F, Desta AT, Ross-Degnan D. Predictors of antibiotic use in African communities: evidence from medicines household surveys in five countries. Trop Med Int Health. 2012; 2: 211-22.
16. WHO. WHO Model List of Essential Medicines, 15th Edition. 2007. [http: //www. who. int/medicines/publications/08_ENGLISH_indexFINAL_ EML15. pdf] Accessed October 20, 2014.
17. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ. 2004; 329(7476): 1212.
18. Crawley J, Chu C, Mtove G, Nosten F. Malaria in children. Lancet. 2010; 375(9724): 1468-81.
19. Cibulskis RE, Aregawi M, Williams R, Otten M, Dye C. Worldwide incidence of malaria in 2009: estimates, time trends, and a critique of methods. PLoS Med. 2011; 8(12): e1001142.
20. O'Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis. 2010; 10(8): 545-55.
21. Thiam S, Thior M, Faye B, Ndiop MÃ, Diouf ML, Diouf MB, et al. Major reduction in anti-malarial drug consumption in Senegal after nation-wide introduction of malaria rapid diagnostic tests. PLoS One. 2011; 6(4): e18419.
22. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, et al. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J. 2011; 10: 326.
23. Buabeng KO, Duwiejua M, Dodoo AN, Matowe LK, Enlund H. Self-reported use of anti-malarial drugs and health facility management of malaria in Ghana. Malar J. 2007; 6(1): 85.
24. Dodoo ANO, Fogg C, Asiimwe A, Nartey ET, Kodua A, Tenkorang O, et al. Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinincombination therapy. Malar J. 2009; 8: 2.
25. Asante KP, Abokyi L, Zandoh C, Owusu R, Awini E, Sulemana A, et al. Community perceptions of malaria and malaria treatment behaviour in a rural district of Ghana: implications for artemisinin combination therapy. BMC Public Health. 2010; 10: 409.
26. Njau JD, Goodman C, Kachur SP, Palmer N, Khatib RA, Abdulla S, et al. Fever treatment and household wealth: the challenge posed for rolling out combination therapy for malaria. Trop Med Int Health. 2006; 11(3): 299-313.
27. Watsierah CA, Jura WG, Oyugi H, Abong'o B, Ouma C. Factors determining anti-malarial drug use in a peri-urban population from malaria holoendemic region of western Kenya. Malar J. 2010; 9: 295.
28. Akweongo P, Agyei-Baffour P, Sudhakar M, Simwaka BN, Konate AT, Adongo PB, et al. Feasibility and acceptability of ACT for the community case management of malaria in urban settings in five African sites. Malar J. 2011; 10: 240.
29. Onyango EO, Ayodo G, Watsierah CA, Were T, Okumu W, Anyona SB, et al. Factors associated with non-adherence to Artemisinin-based Combination Therapy (ACT) to malaria in a rural population from holoendemic region of western Kenya. BMC Infect Dis. 2012; 12(1): 143.
30. Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, et al. Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011; 11(10): 741-9.